Kalpit Patel
Stock Analyst at Wolfe Research
(2.20)
# 3,146
Out of 5,182 analysts
78
Total ratings
44.23%
Success rate
-2.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Downgrades: Peer Perform | n/a | $52.75 | - | 2 | Apr 7, 2026 | |
| GMAB Genmab | Initiates: Outperform | $32 | $26.64 | +20.12% | 1 | Mar 27, 2026 | |
| OLMA Olema Pharmaceuticals | Initiates: Peer Perform | n/a | $15.29 | - | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Initiates: Peer Perform | n/a | $272.75 | - | 1 | Mar 27, 2026 | |
| ONC BeOne Medicines AG | Initiates: Outperform | $340 | $298.90 | +13.75% | 1 | Mar 27, 2026 | |
| CORT Corcept Therapeutics | Upgrades: Peer Perform | n/a | $46.22 | - | 2 | Mar 26, 2026 | |
| AVBP ArriVent BioPharma | Maintains: Buy | $37 → $45 | $30.33 | +48.37% | 2 | Mar 23, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $86.68 | +34.98% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $0.93 | +222.58% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $10.19 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $15.23 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $26.33 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $115.07 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $22.12 | - | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $46.29 | -9.27% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $131.67 | -43.04% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $125.68 | -12.48% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $5.26 | +128.14% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $4.77 | +193.50% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $30.51 | -21.34% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.53 | +128.76% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $5.54 | +62.45% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.21 | +91.94% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $10.08 | +296.83% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $2.69 | +11.52% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $13.50 | +48.15% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $4.21 | +612.59% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $21.00 | +71.43% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.56 | +5,669.23% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.25 | +700.00% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.15 | +334.78% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $11.14 | +797.67% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $26.74 | +180.48% | 2 | Sep 3, 2021 |
Soleno Therapeutics
Apr 7, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $52.75
Upside: -
Genmab
Mar 27, 2026
Initiates: Outperform
Price Target: $32
Current: $26.64
Upside: +20.12%
Olema Pharmaceuticals
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $15.29
Upside: -
Krystal Biotech
Mar 27, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $272.75
Upside: -
BeOne Medicines AG
Mar 27, 2026
Initiates: Outperform
Price Target: $340
Current: $298.90
Upside: +13.75%
Corcept Therapeutics
Mar 26, 2026
Upgrades: Peer Perform
Price Target: n/a
Current: $46.22
Upside: -
ArriVent BioPharma
Mar 23, 2026
Maintains: Buy
Price Target: $37 → $45
Current: $30.33
Upside: +48.37%
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $86.68
Upside: +34.98%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.93
Upside: +222.58%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $10.19
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $15.23
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $26.33
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $115.07
Upside: -
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $22.12
Upside: -
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $46.29
Upside: -9.27%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $131.67
Upside: -43.04%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $125.68
Upside: -12.48%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $5.26
Upside: +128.14%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $4.77
Upside: +193.50%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $30.51
Upside: -21.34%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.53
Upside: +128.76%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.54
Upside: +62.45%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.21
Upside: +91.94%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $10.08
Upside: +296.83%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $2.69
Upside: +11.52%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $13.50
Upside: +48.15%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $4.21
Upside: +612.59%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $21.00
Upside: +71.43%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.56
Upside: +5,669.23%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.25
Upside: +700.00%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.15
Upside: +334.78%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $11.14
Upside: +797.67%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $26.74
Upside: +180.48%